Testing two add-on treatments for schizophrenia in adults with a combined approach
Tests an NMDA-enhancing drug with or without an anti-inflammatory drug in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04917302, who can take part
Where in Taiwan
- Department of Psychiatry, China Medical University HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT04917302
- Record updated
- 23 October 2026
- Original description
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.Read full original descriptionShow less
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.
Inclusion: Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia; Are resistant to adequate treatments of at least two antipsychotics; Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 12-week trial; PANSS total score ≥ 70; Agree to participate in the study and provide informed consent.
Exclusion: DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder; History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study; Clinically significant laboratory screening tests (including blood routine, biochemical tests); Pregnancy or lactation; Inability to follow protocol.